Cleared Traditional

K121951 - LIAISON FT4 LIAISON CONTROL THYROID 1 LIAISON CONTROL THYROID 2 LIAISON CONTROL THYROID 3

K121951 is an FDA 510(k) clearance for LIAISON FT4 LIAISON CONTROL THYROID 1 L..., manufactured by DiaSorin, Inc.. The device is a Class 2 Chemistry device with product code CEC cleared through the Traditional 510(k) pathway after a 275-day FDA review.

K121951 · DiaSorin, Inc. · Chemistry device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Apr 2013
Decision
275d
Days
Class 2
Risk

K121951 is an FDA 510(k) clearance for the LIAISON FT4 LIAISON CONTROL THYROID 1 LIAISON CONTROL THYROID 2 LIAISON CONTR.... Classified as Radioimmunoassay, Free Thyroxine (product code CEC), Class II - Special Controls.

Submitted by DiaSorin, Inc. (Stillwater, US). The FDA issued a Cleared decision on April 4, 2013 after a review of 275 days - an extended review cycle.

This device falls under the Chemistry FDA review panel, regulated under 21 CFR 862.1695 - the FDA in vitro diagnostics and chemistry framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Standard predicate-based submission. Standard predicate reliance. This clearance follows a standard predicate-based equivalence path within the Chemistry review framework, consistent with the majority of Class II 510(k) submissions.

View all DiaSorin, Inc. devices

FDA 510(k) Submission Details - K121951

510(k) Number K121951 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received July 03, 2012
Decision Date April 04, 2013
Days to Decision 275 days
Submission Type Traditional
Review Panel Chemistry (CH)
Summary Summary PDF
Third-party Review No - reviewed directly by FDA
Combination Product No
PCCP Authorized No
Regulatory Context
Review time vs. panel average
187d slower than avg
Panel avg: 88d · This submission: 275d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

CEC Device Classification - Class 2, Special Controls

Product Code CEC Radioimmunoassay, Free Thyroxine
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 862.1695
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Chemistry devices follow this clearance model.

Regulatory Peers - CEC Radioimmunoassay, Free Thyroxine

All 73
Devices cleared under the same product code (CEC) and FDA review panel - the closest regulatory comparables to K121951.
DIMENSION VISTA FREE THYROXINE FLEX REAGENT CARTRIDGE, FT4, DIMENSION VISTA THYROID STIMULATING HORMONE FLEX REAGENT
K140859 · Siemens Healthcare Diagnostics, Inc. · Nov 2014
ELECSYS FT4 II ASSAY, ELECSYS FT4 II CALSET
K131244 · Roche Diagnostics · Jan 2014
ADVIA CENTAUR FT4, ADVIA CENTAUR T4
K132249 · Siemens Healthcare Diagnostics, Inc. · Sep 2013
ABBOTT ARCHITECT FREE T4
K123379 · Abbott Laboratories · Nov 2012
IMMULITE 2000 FREE T4
K083373 · Siemens Healthcare Diagnostics, Inc. · Feb 2009
ACS 180 AND ADVIA CENTAUR FT4 IMMUNOASSAYS
K080167 · Siemens Healthcare Diagnostics · Aug 2008